Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Financial benchmark analysis for 180 SEC-registered companies.
Sector Intelligence · Sprytne.com
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) is led by AMGEN INC with $36.75B in annual revenue. Meanwhile, 4D Molecular Therapeutics, Inc. leads in growth at +230194.6% YoY. The most profitable player is GILEAD SCIENCES, INC. with $8.51B net income.
Based on the latest SEC EDGAR 10-K annual filings · Verified public data
| Rank | Company | Revenue | Details |
|---|---|---|---|
| #1 | AMGEN INCAMGN | $36.75B | YoY: +10.0% |
| #2 | GILEAD SCIENCES, INC.GILD | $29.44B | YoY: +2.4% |
| #3 | BIOGEN INC.BIIB | $9.89B | YoY: +2.2% |
| #4 | NEUROCRINE BIOSCIENCES INCNBIX | $2.86B | YoY: +21.4% |
| #5 | EXELIXIS, INC.EXEL | $2.32B | YoY: +7.0% |
| #6 | Moderna, Inc.MRNA | $1.94B | YoY: -39.9% |
| #7 | HALOZYME THERAPEUTICS, INC.HALO | $1.40B | YoY: +37.6% |
| #8 | BIO-TECHNE CorpTECH | $1.22B | YoY: +5.2% |
| #9 | NOVAVAX INCNVAX | $1.12B | YoY: +64.7% |
| #10 | BIOCRYST PHARMACEUTICALS INCBCRX | $874.8M | YoY: +94.1% |
| #11 | REPLIGEN CORPRGEN | $738.3M | YoY: +16.4% |
| #12 | ADMA BIOLOGICS, INC.ADMA | $510.2M | YoY: +19.6% |
| #13 | Tarsus Pharmaceuticals, Inc.TARS | $451.4M | YoY: +146.7% |
| #14 | Immunocore Holdings plcIMCR | $400.0M | YoY: +29.0% |
| #15 | Krystal Biotech, Inc.KRYS | $389.1M | YoY: +33.9% |
| #16 | Twist Bioscience CorpTWST | $376.6M | YoY: +20.3% |
| #17 | Adaptive Biotechnologies CorpADPT | $277.0M | YoY: +54.8% |
| #18 | Vericel CorpVCEL | $276.3M | YoY: +16.5% |
| #19 | IOVANCE BIOTHERAPEUTICS, INC.IOVA | $263.5M | YoY: +60.6% |
| #20 | REGENXBIO Inc.RGNX | $170.4M | YoY: +104.5% |
| #21 | Ginkgo Bioworks Holdings, Inc.DNA | $170.2M | YoY: -25.1% |
| #22 | Maze Therapeutics, Inc.MAZE | $167.5M | — |
| #23 | Beam Therapeutics Inc.BEAM | $139.7M | YoY: +120.0% |
| #24 | Monte Rosa Therapeutics, Inc.GLUE | $123.7M | YoY: +63.5% |
| #25 | Atara Biotherapeutics, Inc.ATRA | $120.8M | YoY: -6.3% |
| Rank | Company | YoY Growth | Details |
|---|---|---|---|
| #1 | 4D Molecular Therapeutics, Inc.FDMT | +230194.6% | Revenue: $85.2M |
| #2 | Century Therapeutics, Inc.IPSC | +1556.8% | Revenue: $109.2M |
| #3 | X4 Pharmaceuticals, IncXFOR | +1273.2% | Revenue: $35.1M |
| #4 | FENNEC PHARMACEUTICALS INC.FENC | +1244.4% | Revenue: $23.8M |
| #5 | ImmunityBio, Inc.IBRX | +668.3% | Revenue: $113.3M |
| #6 | Autolus Therapeutics plcAUTL | +644.9% | Revenue: $75.4M |
| #7 | TScan Therapeutics, Inc.TCRX | +266.7% | Revenue: $10.3M |
| #8 | Tarsus Pharmaceuticals, Inc.TARS | +146.7% | Revenue: $451.4M |
| #9 | Beam Therapeutics Inc.BEAM | +120.0% | Revenue: $139.7M |
| #10 | Invivyd, Inc.IVVD | +110.5% | Revenue: $53.4M |
| #11 | REGENXBIO Inc.RGNX | +104.5% | Revenue: $170.4M |
| #12 | BIOCRYST PHARMACEUTICALS INCBCRX | +94.1% | Revenue: $874.8M |
| #13 | SUTRO BIOPHARMA, INC.STRO | +65.2% | Revenue: $102.5M |
| #14 | NOVAVAX INCNVAX | +64.7% | Revenue: $1.12B |
| #15 | Monte Rosa Therapeutics, Inc.GLUE | +63.5% | Revenue: $123.7M |
| #16 | IOVANCE BIOTHERAPEUTICS, INC.IOVA | +60.6% | Revenue: $263.5M |
| #17 | Adaptive Biotechnologies CorpADPT | +54.8% | Revenue: $277.0M |
| #18 | Relay Therapeutics, Inc.RLAY | +53.4% | Revenue: $15.4M |
| #19 | Lineage Cell Therapeutics, Inc.LCTX | +53.2% | Revenue: $14.6M |
| #20 | HALOZYME THERAPEUTICS, INC.HALO | +37.6% | Revenue: $1.40B |
| #21 | Krystal Biotech, Inc.KRYS | +33.9% | Revenue: $389.1M |
| #22 | Immunocore Holdings plcIMCR | +29.0% | Revenue: $400.0M |
| #23 | RECURSION PHARMACEUTICALS, INC.RXRX | +26.9% | Revenue: $74.7M |
| #24 | Editas Medicine, Inc.EDIT | +25.4% | Revenue: $40.5M |
| #25 | NEUROCRINE BIOSCIENCES INCNBIX | +21.4% | Revenue: $2.86B |
| Rank | Company | Net Income | Details |
|---|---|---|---|
| #1 | GILEAD SCIENCES, INC.GILD | $8.51B | Margin: 28.9% |
| #2 | AMGEN INCAMGN | $7.71B | Margin: 21.0% |
| #3 | BIOGEN INC.BIIB | $1.29B | Margin: 13.1% |
| #4 | EXELIXIS, INC.EXEL | $782.6M | Margin: 33.7% |
| #5 | NEUROCRINE BIOSCIENCES INCNBIX | $478.6M | Margin: 16.7% |
| #6 | NOVAVAX INCNVAX | $440.3M | Margin: 39.2% |
| #7 | HALOZYME THERAPEUTICS, INC.HALO | $316.9M | Margin: 22.7% |
| #8 | BIOCRYST PHARMACEUTICALS INCBCRX | $263.9M | Margin: 30.2% |
| #9 | Krystal Biotech, Inc.KRYS | $204.8M | Margin: 52.6% |
| #10 | Coherus Oncology, Inc.CHRS | $168.0M | Margin: 452.9% |
| #11 | ADMA BIOLOGICS, INC.ADMA | $146.9M | Margin: 28.8% |
| #12 | BIO-TECHNE CorpTECH | $73.4M | Margin: 6.0% |
| #13 | ELUTIA INC.ELUT | $53.4M | Margin: 434.2% |
| #14 | REPLIGEN CORPRGEN | $48.9M | Margin: 6.6% |
| #15 | Atara Biotherapeutics, Inc.ATRA | $32.7M | Margin: 27.1% |
| #16 | PharmaCyte Biotech, Inc.PMCB | $30.7M | — |
| #17 | Black Diamond Therapeutics, Inc.BDTX | $22.4M | — |
| #18 | Vericel CorpVCEL | $16.5M | Margin: 6.0% |
| #19 | Vaxart, Inc.VXRT | $16.3M | Margin: 221.3% |
| #20 | SAB Biotherapeutics, Inc.SABS | $13.3M | — |
| #21 | Voyager Acquisition Corp./Cayman IslandsVACH | $9.0M | — |
| #22 | CHAMPIONS ONCOLOGY, INC.CSBR | $4.7M | Margin: 8.3% |
| #23 | Abpro Holdings, Inc.ABPO | $2.8M | Margin: 1541.8% |
| #24 | Black Hawk Acquisition CorpBKHA | $1.3M | — |